Zydus Lifesciences climbs on getting USFDA`s tentative approval for Letermovir Tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Zydus Lifesciences is currently trading at Rs. 1020.35, up by 20.85 points or 2.09% from its previous closing of Rs. 999.50 on the BSE.
The scrip opened at Rs. 1009.70 and has touched a high and low of Rs. 1028.45 and Rs. 995.15 respectively. So far 62307 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1028.45 on 26-Mar-2024 and a 52 week low of Rs. 471.10 on 27-Mar-2023.
Last one week high and low of the scrip stood at Rs. 1028.45 and Rs. 946.50 respectively. The current market cap of the company is Rs. 103158.78 crore.
The promoters holding in the company stood at 74.98%, while Institutions and Non-Institutions held 18.03% and 6.99% respectively.
Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) to market Letermovir tablets, 240 mg and 480 mg, (USRLD: Prevymis tablets).
Letermovir tablets are used to prevent disease caused by a virus called cytomegalovirus (CMV) in people who have received a bone marrow transplant or kidney transplant. The drug will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India. Letermovir tablets, 240 mg and 480 mg had annual sales of $289.5 million in the United States (IQVIA MAT Jan-24).
The group now has 393 approvals and has so far filed over 460 ANDAs since the commencement of the filing process in FY 2003-04.
Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.
